APP[V717I] x Tau[P301L] model
Take advantage of InnoSer’s expanded neurology CRO services spanning new Alzheimer’s in vivo research models and expertise
Key characteristics
- Beta-amyloid plaques are observed in the cortex, hippocampus and amygdala
- Tau pathology is observed in the cortex, brainstem, midbrain and at a later age in the hippocampus
- Progressive motoric impairment
- Cognitive deficit in the Morris Water Maze, preceded by an impaired synaptic plasticity
Quantified Methoxy-X04 and AT100 (pTAU S212/T214) IHC staining of 6-13 months old APP[V717I] x Tau[P301L] animals in a specified area of the frontal cortex.
APP[V717I]xTau[P301L] mice develop age-dependent motoric inabilities from ~10 months of age onwards
Quadrant analysis during the probe trial, Morris Water Maze with 9 months- old APP[V717I]xTau[P301L] and age-matched non transgenic control animals (N = 22-23 per group, NE = Target Quadrant)
LTP measurements in CA1 region of 4-6 months-old APP[V717I]xTau[P301L] (biAT) animals compared to wild type animals and other transgenic Alzheimer models (Chong et all, 2011).
Literature
Describing papers
Services
Don’t See Your Model? We Can Help!
Our experts specialize in tailored solutions to meet your unique research needs. Let’s discuss how we can support your project.
Elevate Your Research With Additional Services
Readouts & Analyses
- Full suite of histopathology services
- Immunohistochemistry of brain and nerve tissues (IHC)
- Bioanalyses in various biological matrices
- Flow Cytometry
- ELISA, Ultra-Sensitive ELISA for CSF/plasma biomarkers
- Meso Scale Discovery (MSD)
- Immunoblotting
In Vivo Analyses
- Mouse breeding and genotyping
- Microbiome transplantation studies
- Compound administration
- Stereotaxic surgery
- EEG, EMG and ECG analyses
- Cannula implantation
- Tissue collection and analysis
Stay Curious: More Articles to Explore
![InnoSer Presents New Data on Tau[P301S] and α-Synuclein Combination Models for Neurodegenerative Research at ADPD 2025](https://www.innoserlaboratories.com/wp-content/uploads/2025/03/ADPD-2025-InnoSer-Neurodegenerative-Disease-Models-1080x628.png)
InnoSer Presents New Data on Tau[P301S] and α-Synuclein Combination Models for Neurodegenerative Research at ADPD 2025
We are excited to announce that InnoSer, as an innovative European preclinical neurodegenerative disease CRO, will be actively participating in the upcoming ADPD 2025 conference, taking place in Vienna, Austria from 1st to 5th April 2025. The ADPD 2025 Conference is...
InnoSer Strengthens Neurology Platform with Acquisition of remynd’s CRO Business
InnoSer’s acquisition of remynd’s CRO business further strengthens its neurology platform by integrating specialized neurodegenerative mouse models, expanding its service portfolio for Alzheimer’s and Parkinson’s diseases. Diepenbeek, Belgium – March 4th – InnoSer, a...
Gene Therapy Delivery Strategies: Helping You Address Challenges for CNS Diseases
With several recent gene therapy approvals in the CNS space and more on the horizon, the field of both genetic and neurodegenerative diseases is experiencing a transformative era. However, translating these therapies from preclinical research to clinical application...
How to Advance your Preclinical Research Using Mouse Data to Establish PK/PD Relationships
The major objective of early drug development is to select the most promising compounds and establish safe and effective doses and dosing regimens. To do so, an analysis of both the pharmacokinetic (PK) and pharmacodynamic (PD) properties of your novel compound needs...
AAALAC Accreditation
InnoSer has earned the AAALAC accreditation, demonstrating our commitment to responsible animal care and use. AAALAC International is a nonprofit organization that promotes the humane treatment of animals in science through voluntary accreditation and assessment programs. Our accreditation is valid for three years, incl. 2023. Read more about the AAALAC accreditation programme here.
Animal Welfare
The 3Rs impact everything from policy and regulatory change to the development and uptake of new technologies and approaches. This is why InnoSer has ongoing commitment and monitoring of these processes. The steps we practice maximize our ability to replace, reduce and refine animal involvement and facilitate our commitment to these principles when it comes to research and drug development.
info@innoserlaboratories.com